Top Markets
#1 EXOD EXOD +56.80%
#2 CoW Protocol CoW Protocol +54.01%
#3 Glidr Glidr +41.01%
#4 Cysic Cysic +38.33%
#5 Walrus Walrus +27.54%
#6 Humanity Humanity +25.25%
#7 Enso Enso +17.24%
#8 Tutorial Tutorial +15.94%
#9 The Black Bull The Black Bull +14.95%
#10 Codatta Codatta +14.84%
Coin of the day
EXOD EXOD
Settings
Language
ENGLISH
Currency
USD
Theme
DermTech, Inc. DermTech, Inc.

DermTech, Inc.

DMTK
Rank in Stocks #37065
DermTech, Inc., a molecular diagnostics firm headquartered in La Jolla,... DermTech, Inc., a molecular diagnostics firm headquartered in La Jolla, California, specializes in creating and bringing to market advanced, non-invasive genomic tests. Operating within the United States, their innovative solutions facilitate the diagnosis of various dermatological issues, including skin cancer, inflammatory conditions, and age-related skin concerns. A cornerstone of their offerings is the DermTech Melanoma Test (DMT), a sophisticated gene expression analysis. This assay plays a crucial role in enhancing the early identification of genomic abnormalities, effectively aiding in the exclusion of melanoma and often removing the need for invasive surgical biopsies of suspicious pigmented lesions. The company further provides specialized adhesive kits for convenient skin sample collection. Additionally, they offer gene expression assays designed to analyze key inflammatory pathways such, as Th1, Th2, IFN-gamma, and Th17. Looking ahead, DermTech is actively developing a pipeline of new products, which includes DNA risk assessment tools for UV damage, diagnostic tests for non-melanoma skin cancers, and rule-out tests for cutaneous T-cell lymphoma. They also extend their services by delivering health-related information and support through digital and telecommunication platforms. DermTech's diagnostic products and services are primarily targeted towards medical professionals in the fields of pathology and oncology.
Share Price
$0.069
Last synced: 2024-07-22
Market Cap
$2.06M
Change (1 day)
-1.43%
Change (1 year)
0.00%
Country
US
Trade DermTech, Inc. (DMTK)

Category

Healthcare
P/E ratio for DermTech, Inc. (DMTK)
P/E ratio as of August 2026 TTM: -0.03
According to DermTech, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.03. At the end of 2022 the company had a P/E ratio of -0.46.
P/E ratio history for DermTech, Inc. from 2016 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) -0.03 -94.37%
2023 -0.54 17.86%
2022 -0.46 -92.18%
2021 -5.83 -61.42%
2020 -15.10 249.93%
2019 -4.32 -102.06%
2018 209.29 -100.01%
2017 -3.00M 4,455.00%
2016 -65.77K 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
TMO.US
 31.59 -104,029.28%
US
Danaher Corporation Danaher Corporation
Danaher Corporation
DHR.US
 35.83 -117,968.09%
US
WuXi AppTec Co., Ltd. WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd.
603259.SS
 - -
CN
Natera, Inc. Natera, Inc.
Natera, Inc.
NTRA.US
 -227.89 749,537.17%
US
IDEXX Laboratories, Inc. IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
IDXX.US
 38.69 -127,373.03%
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.